Objectives The objectives of this study were to determine the effects of obesity on unbound
trough concentrations and on the achievement of pharmacokinetic (PK)/pharmacodynamic …

Background: Complicated intra-abdominal infections (cIAI) are a common problem in
surgical practice. The effect of body mass index (BMI) on the outcome is poorly understood …

Although the dose of some drugs is commonly adjusted for weight, weight-related dosage
adjustments are rarely made for most antimicrobials. We reviewed the English-language …

Obesity is a global pandemic affecting 33% of adults in the United States. Obese persons
receiving cefazolin or fluconazole have been shown to have worse outcomes with …

Ertapenem, a carbapenem antibacterial, has in vitro activity against many Gramnegative
(including Enterobacteriaceae) and Gram-positive aerobic and anaerobic bacteria that are …

Ertapenem is a carbapenem that shares the activity of imipenem and meropenem against
most species, but is less active against non-fermenters. Activity is retained against most …

The combination of cefepime with AAI101, a novel extended-spectrum β-lactamase inhibitor,
possesses potent in vitro activity against many resistant Gram-negative pathogens. Against …

Background Imipenem/funobactam (formerly XNW4107) is a novel β-lactam/β-lactamase
inhibitor with activity against MDR Acinetobacter baumannii, Pseudomonas aeruginosa and …

Meropenem-vaborbactam is a fixed-dose beta-lactam/beta-lactamase inhibitor with potent in
vitro and in vivo activity against Klebsiella pneumoniae carbapenemase (KPC)-producing …

Few data exist concerning the effect of obesity on the pharmacokinetic parameters of
vancomycin. The purpose of this investigation was to assess the effect of obesity on …